1. Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer;Modi;Cancer Res,2021
2. André F, Park YH, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet [Internet]. 2023. Available at https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00725-0/fulltext. Cited April 30, 2023.
3. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer;Modi;N Engl J Med,2022
4. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020
5. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012